BEN-301

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameBEN-301
Drug Alias NameBEN301BEN-301
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > CAR-TregsCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs > CAR-Tregs
Mechanisms of ActionRegulatory T-lymphocytes modulatorsT-cell surface antigen CD4 modulatorsForkhead box protein P3 modulators
TargetsT-cell surface antigen CD4Forkhead box protein P3
Therapy Area/IndicationsScleroderma, SystemicMyositisSjogren's Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co LtdRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicMyositisSjogren's Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A